Acoramidis for the Treatment of Transthyretin Cardiac Amyloidosis

By afschroeder • October 31, 2025

Pillai AA, Mogga B, Passey S, Frishman WH, Aronow WS. Acoramidis for the Treatment of Transthyretin Cardiac Amyloidosis. Cardiol Rev. 2025 Oct 20. doi: 10.1097/CRD.0000000000001074. Epub ahead of print. PMID: 41166689.

Tags: acoramidis, cardiac amyloidosis, Cardiology/Epi, Harbor UCLA, heart failure, Publications, transthyretin stabilizer

Clinical outcomes among individuals with systemic inflammation following myocardial infarction: Insights from the veterans affairs healthcare system

Sandhu AT, Furst A, Rodriguez F, Kalwani N, Maron DJ, Nallamshetty S, Din N, Fan M, Khachatourian K, Skaar JR, Tonnu-Mihara I. Clinical outcomes among[...]

Age and sex specific coronary plaque characteristics among South Asians: Insights from the DILWALE CTA study

Satish P, Vajramani A, Gupta S, Ma TW, Prasad T, Lakshmanan S, Budoff M, Kalra DK, Khan MS, Leipsic J, Alsaid A, Kulkarni A. Age[...]

Comparing incidence of heart failure in individuals with enlarged cardiac chambers versus diabetes

Mirjalili SR, Atlas K, Reeves AP, Zhang C, Wasserthal J, Azimi A, Hashemi A, Mozafarybazargany M, Ghaffari Jolfayi A, Atlas T, Henschke CI, Yankelevitz DF,[...]